Atara Will Join Forces with Merck for Clinical Trial

Atara Biotherapeutics (NASDAQ:ATRA) announced a clinical trial collaboration agreement with Merck (NYSE:MRK) for an upcoming Phase 1/2 trial, that will see them combining their drugs to treat patients with Nasopharyngeal carcinoma.

As quoted in the press release

[The trial will] evaluate Atara Bio’s allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL), or ATA129, in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with platinum resistant or recurrent EBV-associated NPC.

Atara Bio’s ATA129 is an investigational therapy in which a healthy donor’s T-cells are stimulated to recognize EBV antigens, or viral proteins, expressed in the cells of certain liquid and solid tumors. ATA129 has previously been evaluated as a single agent in Phase 1 and 2 trials that enrolled patients with a variety of EBV-positive malignancies including 14 patients with chemotherapy refractory, metastatic NPC. In these trials, evidence of radiographic response was observed and EBV-CTLs were also shown to expand after administration without concomitant lymphodepleting chemotherapy. Recent studies suggest that EBV upregulates the transcription of PD-L1 in EBV-associated solid tumors such as NPC and gastric cancer, suggesting the potential for synergy in combination with anti-PD-1 therapies, such as KEYTRUDA.

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.


Leave a Reply